Almitas Capital LLC Increases Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Almitas Capital LLC lifted its holdings in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 69.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,626,896 shares of the company's stock after acquiring an additional 665,968 shares during the quarter. Zentalis Pharmaceuticals makes up 1.1% of Almitas Capital LLC's portfolio, making the stock its 18th biggest position. Almitas Capital LLC owned 2.28% of Zentalis Pharmaceuticals worth $4,929,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the stock. Prudential Financial Inc. purchased a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter worth $39,000. Cerity Partners LLC purchased a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at $40,000. Ieq Capital LLC purchased a new stake in Zentalis Pharmaceuticals during the fourth quarter valued at $46,000. Oxford Asset Management LLP bought a new position in Zentalis Pharmaceuticals in the fourth quarter worth approximately $52,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Zentalis Pharmaceuticals during the 4th quarter valued at about $53,000.

Insider Buying and Selling

In related news, insider Ingmar Bruns acquired 20,000 shares of the stock in a transaction that occurred on Thursday, February 6th. The stock was purchased at an average price of $2.28 per share, with a total value of $45,600.00. Following the transaction, the insider now owns 36,629 shares of the company's stock, valued at approximately $83,514.12. This trade represents a 120.27 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Scott Dunseth Myers acquired 21,000 shares of the company's stock in a transaction that occurred on Wednesday, April 30th. The stock was acquired at an average price of $1.40 per share, with a total value of $29,400.00. Following the acquisition, the director now directly owns 281,192 shares of the company's stock, valued at approximately $393,668.80. This represents a 8.07 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 3.60% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on ZNTL shares. Wedbush reissued a "neutral" rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, March 28th. UBS Group decreased their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a report on Thursday, March 27th. Finally, Wells Fargo & Company lowered their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating for the company in a research report on Thursday, January 30th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $8.24.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL traded down $0.01 during trading hours on Wednesday, hitting $1.25. The stock had a trading volume of 392,399 shares, compared to its average volume of 1,543,906. The firm has a market capitalization of $89.58 million, a price-to-earnings ratio of -0.50 and a beta of 1.81. Zentalis Pharmaceuticals, Inc. has a fifty-two week low of $1.01 and a fifty-two week high of $13.24. The firm has a 50-day moving average price of $1.54 and a 200 day moving average price of $2.43.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its quarterly earnings data on Wednesday, March 26th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.09. The firm had revenue of $26.90 million during the quarter. As a group, analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.